Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting

022 SID Congress Report Blog Graphic

The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The meeting was held as a hybrid, in-person meeting in Portland, Oregon, with virtual access to pre-recorded lectures and posters available afterward. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.

EUGENE FARBER LECTURE

Each year, the prestigious Eugene Farber lecture is awarded to an eminent psoriasis investigator. This year, the lecture was awarded to the IPC Board Member Dr. Johann Gudjonsson, MD, PhD. The lecture was titled Has the Riddle of Psoriasis Been Finally Solved – Is it Time to Move On?” Dr. Gudjonsson discussed the impressive advances in psoriasis research in the past two decades. Yet, Dr. Gudjonsson explains the obstacles that must be extensively addressed in future psoriasis research, and no, “it is not yet time to move on.”

IPC SYMPOSIUM LECTURES

  • April Armstrong, MD, MPH, IPC Councilor, presented “Real-World Data Using Medical and Administrative Records.” She focused on the advantages and disadvantages of administrative claims data retrieved from insurance companies versus electronic health/medical records data. She discussed their application in research work and considerations by regulatory authorities.
  • Dr. Nick Reynolds, BSc, MBBS, MD, FRCP, IPC Councilor, presented “Real-World Data and Psoriasis: A European Perspective.” He explained the strengths and weaknesses of real-world data and registries and presented interesting results from psoriasis registries.
  • Alexis Ogdie, MD, MSCE, presented “Innovations in Real-World Data.” She discussed the knowledge gaps that real-world data can answer, explained pragmatic trials, and highlighted future opportunities for innovation of real-world data.

IPC SYMPOSIUM POSTER PRESENTATIONS

  • Manan Mehta, BS, presented “Your Pores and the Outdoors: Investigating the Association between Pollution and Inflammatory Dermatological Diseases,”– a study highlighting a significant relationship between air pollution (Particulate Matter 2.5) and three inflammatory skin conditions; psoriasis, atopic dermatitis, and hidradenitis suppurativa.
  • George Gondo, MA, the National Psoriasis Foundation (NPF), presented “Understanding Health Disparities among Patients with Psoriasis: Results from National Psoriasis Foundation Annual Surveys 2019 – 2021”. The survey showed the presence of considerable health disparities and differences in psoriasis severity among psoriasis patients of different ethnic groups.
  • Dr. Andrew Blauvelt, MD, MBA, IPC Board Member, presented “Psoriasis Resolution in Challenging Body Areas with Ixekizumab: Response Trajectories by Patient Profile Clusters Over Time.” The study applied machine learning to define Ixekizumab-response clusters. It concluded a rapid and stable complete clearance, including resolution of nail, scalp, and palmoplantar psoriasis with Ixekizumab for most patients.
  • Dr. Megan H Noe, MD, MPH, MSCE, presented “The Patient Perspective on Vaccine Uptake in Adults with Psoriasis and Eczema.” The study showed that psoriasis and eczema patients identified access to appointments and side effects concerns as the most common barriers to receiving recommended adult vaccinations.
  • Dr. Qinmengge Li, BS, MS, presented “Kullback-Leibler Divergence Model to Integrate Genetic and Genomic Information to Assess Drug Response for Psoriatic Patients.” This study revealed the feasibility of using statistical techniques to integrate and analyze information from two independent sets of genetic and genomic data to assess drug response and improve the prognostic prediction accuracy.
  • Dr. Álvaro Gonzales-Cantero, MD, PhD, 2021 IPC Fellow, presented “HDL Composition, Particle Number and Size is Associated with Non-Calcified Coronary Plaque in Psoriasis.” The study concluded that measuring HDL particle number and size using magnetic resonance spectroscopy can be a biomarker for the early detection of subclinical atherosclerosis in psoriasis.
  • Michael D Howell, PhD, presented “A Novel Expression Based, Non-Invasive Method to Differentiate Atopic Dermatitis and Psoriasis.” This study demonstrates the use of non-invasive epidermal skin samples to differentiate psoriasis from atopic dermatitis patients based on a molecular RNA signature of IL-13, CCL17, IL-17A, and NOS2.
Finally, the growing role of artificial intelligence and machine learning in psoriasis research was well-recognized in the scientific sessions of the meeting. For a more in-depth read, please download the full report.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026